1[1]Massarella JW,He GZ,Dorr A,et al.The pharmacyokinetics and tolerability of the oral neuralminidase inhibitor oseltamivir in healthy adult and ederly volunteers[J].J Clin Pharmacol,2000,40:836 被引量：1
2[2]Centers for Disease Control and Prevention.Prevention and control of influenza:recommendations of the Advisory Committee on Immunization Practices(ACIP) [C].MMWR Morb Mortal Wkly Rep,2000,49(RR-03) :1 被引量：1
3[3]Musich SA,Burton WN,Edington DW.Costs and benefits of prevention and disease management[J].Dis Manage Health Outcomes,1999,5:153 被引量：1
4[4]He G,Massarella J,Wand P.Clinical pharmacyokinetics of the prodrug oseltamivir and its active metabolite Ro 64 -0802 [J].Clin Pharmacokinet,1999,37:471 被引量：1
5[5]Hay AJ.The action of adamantanamines against influenza A viruses:inhibition of the M2 ion channel protein[J].Semin Virol,1992,3:21 被引量：1
6[6]Centers for Disease Control and Prevention.Prevention and control of influenza:recommendations of the Advisory comm.ittee on Immunization Practices(ACIP) [C].MMWR Morb Mortal Wkly Rep,1998,47(RR-0) :1 被引量：1
